{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Related AEs"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Related SAEs"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Related Grade 3 or 4 AEs"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"Safe patients from related AEs"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Number of patients with treatment-related AEs (Grade 3 and 4 AEs and serious adverse events \\[SAEs\\]) by using the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v.5.0.","groups":[{"description":"Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.\n\nRetifanlimab: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.","id":"OG000","title":"Interventional Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From baseline until disease progression or treatment discontinuation, up to 10.3 months","title":"Safety Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}